SFA Therapeutics Strengthens Intellectual Property in Autoimmune Disease and Hepatocellular Carcinoma
JENKINTOWN, Pa., Oct. 22, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the expansion of


